fbpx Skip to main content

WEDNESDAY, Oct. 14, 2020 (HealthDay News) — Black and Mixed/Other ethnicity are independently associated with greater hospital admission risk due to COVID-19 but are not associated with in-hospital mortality risk, according to a U.K. study published online Oct. 9 in EClinicalMedicine.

Rosita Zakeri, from King’s College London in the United Kingdom, and colleagues examined whether ethnic background affects the risk for hospital admission with severe COVID-19 and/or in-hospital mortality using data from 872 inner-city adult residents admitted to the hospital with confirmed COVID-19 and 3,488 matched controls randomly sampled from a primary health care database.

The researchers found that Black and Mixed/Other ethnicity were associated with higher hospital admission risk than White ethnicity (odds ratio [OR], 3.12 and 2.97, respectively). When adjusting for comorbidities and deprivation, this association was modestly reduced (OR, 2.24 for Black, 2.70 for Mixed/Other ethnicity). There was no association for higher admission risk with Asian ethnicity (adjusted OR, 1.01; 95 percent confidence interval [CI], 0.70 to 1.46). Among 1,827 adults consecutively admitted with COVID-19, 28.9 percent died during a median of eight days. Black race (adjusted hazard ratio [HR], 1.06; 95 percent CI, 0.82 to 1.37) and Mixed/Other ethnicity (adjusted HR, 0.72; 0.47-1.10) were not associated with in-hospital mortality; an association was observed for Asian ethnicity (adjusted HR, 1.71; 95 percent CI, 1.15-2.56).

“A substantial component of the increased risk in both settings remains after adjusting for deprivation measures and comorbidities, suggesting that additional ethnicity-related factors are important,” the authors write.

One author disclosed ties to the pharmaceutical and biotechnology industries.

You May Also Like::  Telemedicine Use Continues to Explode During Pandemic

Abstract/Full Text

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More